A deep dive into why this therapy has demonstrated effectiveness in various areas, including for tumors.
Related Posts
Semaglutide Associated with Optic Neuropathy That Can Lead to Blindness, FDA Approves Lilly’s Kisunla & more
FDA Approves Lilly’s Kisunla for the Treatment of Early Symptomatic Alzheimer’s Disease Kisunla is the first amyloid plaque-targeting therapy that…
The Case for Reshoring Manufacturing to the United States
In a video interview with Pharma Commerce, Brad Stewart, BDO’s national life sciences co-leader, describes the challenges that tariffs may…
Overcoming Regulatory Barriers to Market Access
As international price referencing tightens and payer expectations rise, companies face a shrinking margin for error. The panel explores how…